The future of the pharmaceutical market will be determined by biologics – drugs produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. What are the products that lead the market now and what can we expect to see in the coming years?
Find out in Kalorama Information’s report, What’s Next in Biologics?, which represents our latest research into the market for non-vaccine biological drugs and the companies who compete in the market.
The following are among the data points in this report:
- Biopharmaceutical Pipeline for Significant Companies
- Market Size of Biopharmaceuticals
- Monoclonal Antibodies (mAbs)
- Recombinant Hormones and Proteins (rDNA)
- Interferons and
- Other Biologics
- Biopharmaceutical Market Forecast to 2015
- Products in Development: New Compound vs. Additional Indications
- Competitor Market Shares for Biopharmaceuticals
- Autoimmune, Cancer, Cardiovascular and Hormone Treatments Market Sizes and Competitor Shares
- Drug Development Cost Progression
- Leading Biotech Therapies by 2010 Revenues
- Population and Healthcare Spending Trends
- Select Biotechnology Drugs Approved for Marketing
The biologics industry encompasses a wide range of products including monoclonal antibodies, blood products, vaccines, and some diagnostics and devices. For the purpose of this study, Kalorama Information focuses on those biologics that are used in conjunction with, or as a replacement to, traditional pharmaceutical treatments. For example, treatments for cancer, growth disorders, autoimmune diseases and blood disorders. This study excludes products such as vaccines—including prophylactic vaccines—which are covered in-depth in separate Kalorama studies.
The following topics are among the qualitative analysis found in this report:
- The Role Government Incentives Will Play in the Future Biotech Market
- Pharmaceutical Regulatory Exclusivity
- Biosimilars: Where They Stand and What We Can Expect
- The Largest Areas of Research for Biopharmaceuticals
- Improvements in the Next Generation of Biologics
- The Impact of Aging Populations on Biotechnology Market Development
- Health Care Reform: What it Means
- Recent Mergers, Acquisitions, and Collaborations
- Contributors to R&D Success
- Targeted Cancer Therapy
- Genome Sequencing for Personalized Healthcare
- The Role of Contract Research Organizations
In the traditional pharmaceutical market, the pipeline is struggling to produce strong therapies and the growing number of drugs losing patent protection will more than offset revenues generated from new developments. For now, the biotechnology market is spared the impact of this setback as the path to generic or biosimilar development is more involved and the number of biotechnology drugs facing generic competition remains limited. Many companies are capitalizing on this trend, and among those discussed in the report include the following:
- Abbott Laboratories
- Biogen Idec
- Johnson & Johnson
- Merck & Co.
- Merck Serono
- Novo Nordisk
All Kalorama reports advertise the single user price. Use is limited to one user. We also feature department and global pricing for reports that we be utilized by more than one user at your company. Please consult ask your sales representative or select the correct license on our website.
For Kalorama’s take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information’s Key Point Blog at http://kaloramakeypoint.blogspot.com/